News und Analysen

Shares of CRISPR Therapeutics (NASDAQ: CRSP) were jumping 10.1% higher as of 10:58 a.m. ET on Friday. The solid move followed Thursday's gain of more than 8%.

There's a good reason for this

Shares of CRISPR Therapeutics (NASDAQ: CRSP) were jumping 10.1% higher as of 10:58 a.m. ET on Friday. The solid move followed Thursday's gain of more than 8%.

There's a good reason for this

Shares of CRISPR Therapeutics (NASDAQ: CRSP) were jumping 10.1% higher as of 10:58 a.m. ET on Friday. The solid move followed Thursday's gain of more than 8%.

There's a good reason for this

With shares of DexCom (NASDAQ: DXCM) falling 11% this year amid a steadily rising market, one might think that the medical device maker's growth potential is ebbing compared to its former glory. But

With shares of DexCom (NASDAQ: DXCM) falling 11% this year amid a steadily rising market, one might think that the medical device maker's growth potential is ebbing compared to its former glory. But

Getting to $1 million is a great long-term goal for investors to target. Not only could that be a good nest egg to tap into during retirement, but you could also use that money to invest in dividend

Getting to $1 million is a great long-term goal for investors to target. Not only could that be a good nest egg to tap into during retirement, but you could also use that money to invest in dividend

If past performance guaranteed future success, Vertex Pharmaceuticals (NASDAQ: VRTX) would be one of the best biotech stocks to invest in. The drugmaker has consistently outperformed the broader

If past performance guaranteed future success, Vertex Pharmaceuticals (NASDAQ: VRTX) would be one of the best biotech stocks to invest in. The drugmaker has consistently outperformed the broader

If past performance guaranteed future success, Vertex Pharmaceuticals (NASDAQ: VRTX) would be one of the best biotech stocks to invest in. The drugmaker has consistently outperformed the broader

The past five years haven't been great for medical device maker Medtronic (NYSE: MDT). Normally investors would expect a stock to generate positive gains over a five-year period, but Medtronic's

AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) are makers of two of the world's top-selling pharmaceutical products. AbbVie's immunology drug Humira brought in peak sales of more than $21 billion, while

AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) are makers of two of the world's top-selling pharmaceutical products. AbbVie's immunology drug Humira brought in peak sales of more than $21 billion, while

As far as healthcare stocks go, drugmaker Merck (NYSE: MRK) and medical device expert Intuitive Surgical (NASDAQ: ISRG) haven't been the best of the bunch this year. Both are lagging the market in

Wall Street traders have numerous (and often creative) strategies to speculate on stocks and their up and down price movements. There are times when the prices of stocks are influenced more by what

Both Pfizer (NYSE: PFE) and Novo Nordisk (NYSE: NVO) can claim to investors that plenty more growth is on the way. With new markets beckoning and multi-year strategic plans in full swing, both of

Both Pfizer (NYSE: PFE) and Novo Nordisk (NYSE: NVO) can claim to investors that plenty more growth is on the way. With new markets beckoning and multi-year strategic plans in full swing, both of

Almost like clockwork, Halloween ended, stores started setting up for the all-important holiday shopping season, and the stock market started what could potentially end up as one heck of an early

Almost like clockwork, Halloween ended, stores started setting up for the all-important holiday shopping season, and the stock market started what could potentially end up as one heck of an early